FMR LLC has disclosed a significant ownership stake in Silence Therapeutics plc, holding 7.1% of the company’s common stock. This filing, made on November 5, 2026, is noteworthy as it reflects growing institutional interest in the pharmaceutical preparations sector.

Silence Therapeutics, incorporated in London, specializes in developing innovative therapies using RNA interference technology. The company is publicly traded on the Nasdaq and OTC markets under the tickers SLN and SLNCF, respectively. The recent filing comes after a series of other filings, including two DEFA14A forms and an 8-K, all submitted on October 19, 2026, highlighting ongoing corporate activities.

The Schedule 13G filing indicates that FMR LLC beneficially owns 13,180,206 shares of Silence Therapeutics. This ownership gives FMR LLC sole voting and dispositive power over the shares, suggesting a strong commitment to the company’s future. Abigail P. Johnson, the Chairman and CEO of FMR LLC, is also noted in the filing as having a significant role in the company.

FMR LLC’s investment may impact various stakeholders, including existing shareholders and potential investors, as it underscores confidence in Silence Therapeutics’ business model and growth potential. The filing notes that no other individual holds more than 5% of the common stock, indicating FMR LLC's position as a key player among shareholders.

The filing does not specify what actions may follow this disclosure, leaving future developments open-ended. However, the substantial stake held by FMR LLC could lead to increased engagement in the company’s strategic direction and operational decisions.